Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 7.834
Filtrer
1.
Int J Mol Sci ; 25(12)2024 Jun 20.
Article de Anglais | MEDLINE | ID: mdl-38928469

RÉSUMÉ

The SPRY domain-containing SOCS box proteins SPSB1, SPSB2, and SPSB4 utilize their SPRY/B30.2 domain to interact with a short region in the N-terminus of inducible nitric oxide synthase (iNOS), and recruit an E3 ubiquitin ligase complex to polyubiquitinate iNOS, resulting in the proteasomal degradation of iNOS. Inhibitors that can disrupt the endogenous SPSB-iNOS interactions could be used to augment cellular NO production, and may have antimicrobial and anticancer activities. We previously reported the rational design of a cyclic peptide inhibitor, cR8, cyclo(RGDINNNV), which bound to SPSB2 with moderate affinity. We, therefore, sought to develop SPSB inhibitors with higher affinity. Here, we show that cyclic peptides cR7, cyclo(RGDINNN), and cR9, cyclo(RGDINNNVE), have ~6.5-fold and ~2-fold, respectively, higher SPSB2-bindng affinities than cR8. We determined high-resolution crystal structures of the SPSB2-cR7 and SPSB2-cR9 complexes, which enabled a good understanding of the structure-activity relationships for these cyclic peptide inhibitors. Moreover, we show that these cyclic peptides displace full-length iNOS from SPSB2, SPSB1, and SPSB4, and that their inhibitory potencies correlate well with their SPSB2-binding affinities. The strongest inhibition was observed for cR7 against all three iNOS-binding SPSB proteins.


Sujet(s)
Peptides cycliques , Peptides cycliques/composition chimique , Peptides cycliques/pharmacologie , Humains , Protéines SOCS/composition chimique , Protéines SOCS/métabolisme , Nitric oxide synthase type II/antagonistes et inhibiteurs , Nitric oxide synthase type II/métabolisme , Nitric oxide synthase type II/composition chimique , Oligopeptides/composition chimique , Oligopeptides/pharmacologie , Liaison aux protéines , Relation structure-activité
2.
Proc Natl Acad Sci U S A ; 121(26): e2321710121, 2024 Jun 25.
Article de Anglais | MEDLINE | ID: mdl-38885377

RÉSUMÉ

Somatostatin receptor 5 (SSTR5) is an important G protein-coupled receptor and drug target for neuroendocrine tumors and pituitary disorders. This study presents two high-resolution cryogenicelectron microscope structures of the SSTR5-Gi complexes bound to the cyclic neuropeptide agonists, cortistatin-17 (CST17) and octreotide, with resolutions of 2.7 Å and 2.9 Å, respectively. The structures reveal that binding of these peptides causes rearrangement of a "hydrophobic lock", consisting of residues from transmembrane helices TM3 and TM6. This rearrangement triggers outward movement of TM6, enabling Gαi protein engagement and receptor activation. In addition to hydrophobic interactions, CST17 forms conserved polar contacts similar to somatostatin-14 binding to SSTR2, while further structural and functional analysis shows that extracellular loops differently recognize CST17 and octreotide. These insights elucidate agonist selectivity and activation mechanisms of SSTR5, providing valuable guidance for structure-based drug development targeting this therapeutically relevant receptor.


Sujet(s)
Octréotide , Récepteur somatostatine , Récepteur somatostatine/métabolisme , Récepteur somatostatine/agonistes , Récepteur somatostatine/composition chimique , Humains , Octréotide/composition chimique , Octréotide/pharmacologie , Octréotide/métabolisme , Neuropeptides/métabolisme , Neuropeptides/composition chimique , Cryomicroscopie électronique , Liaison aux protéines , Peptides cycliques/composition chimique , Peptides cycliques/pharmacologie , Peptides cycliques/métabolisme , Somatostatine/métabolisme , Somatostatine/composition chimique , Somatostatine/analogues et dérivés , Modèles moléculaires , Cellules HEK293
3.
BMC Microbiol ; 24(1): 227, 2024 Jun 27.
Article de Anglais | MEDLINE | ID: mdl-38937715

RÉSUMÉ

This study investigated the influence of bacterial cyclic lipopeptides (LP; surfactins, iturins, fengycins) on microbial interactions. The objective was to investigate whether the presence of bacteria inhibits fungal growth and whether this inhibition is due to the release of bacterial metabolites, particularly LP. Selected endophytic bacterial strains with known plant-growth promoting potential were cultured in the presence of Fusarium oxysporum f.sp. strigae (Fos), which was applied as model fungal organism. The extracellular metabolome of tested bacteria, with a focus on LP, was characterized, and the inhibitory effect of bacterial LP on fungal growth was investigated. The results showed that Bacillus velezensis GB03 and FZB42, as well as B. subtilis BSn5 exhibited the strongest antagonism against Fos. Paraburkholderia phytofirmans PsJN, on the other hand, tended to have a slight, though non-significant growth promotion effect. Crude LP from strains GB03 and FZB42 had the strongest inhibitory effect on Fos, with a significant inhibition of spore germination and damage of the hyphal structure. Liquid chromatography tandem mass spectrometry revealed the production of several variants of iturin, fengycin, and surfactin LP families from strains GB03, FZB42, and BSn5, with varying intensity. Using plate cultures, bacillomycin D fractions were detected in higher abundance in strains GB03, FZB42, and BSn5 in the presence of Fos. Additionally, the presence of Fos in dual plate culture triggered an increase in bacillomycin D production from the Bacillus strains. The study demonstrated the potent antagonistic effect of certain Bacillus strains (i.e., GB03, FZB42, BSn5) on Fos development. Our findings emphasize the crucial role of microbial interactions in shaping the co-existence of microbial assemblages.


Sujet(s)
Antibiose , Antifongiques , Bacillus , Fusarium , Lipopeptides , Fusarium/effets des médicaments et des substances chimiques , Fusarium/croissance et développement , Lipopeptides/pharmacologie , Lipopeptides/métabolisme , Bacillus/métabolisme , Antifongiques/pharmacologie , Peptides cycliques/pharmacologie , Interactions microbiennes , Burkholderiaceae/croissance et développement , Burkholderiaceae/métabolisme , Spores fongiques/effets des médicaments et des substances chimiques , Spores fongiques/croissance et développement , Hyphae/effets des médicaments et des substances chimiques , Hyphae/croissance et développement
4.
Mar Drugs ; 22(6)2024 Jun 06.
Article de Anglais | MEDLINE | ID: mdl-38921573

RÉSUMÉ

Three new cyclic lipopeptides, olenamidonins A-C (1-3), in addition to two previously reported metabolites (4 and 5), were accumulated in the ΔdtxRso deletion mutant of deepsea-derived Streptomyces olivaceus SCSIO 1071. The structures of these cyclic lipopeptides were determined by a combination of spectroscopic methods and circular dichroism (CD) measurement. The antibacterial assay results showed that compounds 1-5 displayed different degrees of growth inhibition against multidrug-resistant (MDR) bacterial strains Enterococcus faecalis CCARM 5172 and Enterococcus faecium CCARM 5203 with minimum inhibitory concentrations (MICs) of 1.56-6.25 µg/mL.


Sujet(s)
Antibactériens , Enterococcus faecalis , Lipopeptides , Tests de sensibilité microbienne , Peptides cycliques , Streptomyces , Streptomyces/génétique , Streptomyces/métabolisme , Lipopeptides/pharmacologie , Lipopeptides/isolement et purification , Antibactériens/pharmacologie , Antibactériens/composition chimique , Antibactériens/isolement et purification , Enterococcus faecalis/effets des médicaments et des substances chimiques , Peptides cycliques/pharmacologie , Peptides cycliques/composition chimique , Peptides cycliques/isolement et purification , Enterococcus faecium/effets des médicaments et des substances chimiques , Multirésistance bactérienne aux médicaments/effets des médicaments et des substances chimiques , Protéines bactériennes/génétique
5.
Mar Drugs ; 22(6)2024 Jun 12.
Article de Anglais | MEDLINE | ID: mdl-38921582

RÉSUMÉ

Cyclic glycine-proline (cGP), a prevalent marine cyclic dipeptide, possesses a distinct pyrrolidine-2,5-dione scaffold, which contributes to the chemical diversity and broad bioactivities of cGP. The diverse sources from marine-related, endogenous biological, and synthetic pathways and the in vitro and in vivo activities of cGP are reviewed. The potential applications for cGP are also explored. In particular, the pivotal roles of cGP in regulating insulin-like growth factor-1 homeostasis, enhancing neuroprotective effects, and improving neurotrophic function in central nervous system diseases are described. The potential roles of this endogenous cyclic peptide in drug development and healthcare initiatives are also highlighted. This review underscores the significance of cGP as a fundamental building block in drug discovery with exceptional drug-like properties and safety. By elucidating the considerable value of cGP, this review aims to reignite interest in cGP-related research within marine medicinal chemistry and synthetic biology.


Sujet(s)
Organismes aquatiques , Dipeptides , Peptides cycliques , Animaux , Dipeptides/pharmacologie , Dipeptides/composition chimique , Peptides cycliques/pharmacologie , Peptides cycliques/composition chimique , Humains , Neuroprotecteurs/pharmacologie , Neuroprotecteurs/composition chimique , Découverte de médicament/méthodes , Glycine/pharmacologie , Glycine/analogues et dérivés
6.
Mar Drugs ; 22(6)2024 Jun 16.
Article de Anglais | MEDLINE | ID: mdl-38921593

RÉSUMÉ

Four new cyclic pentapeptides, avellanins D-G (1-4), together with four known compounds (5-8), were isolated from a mangrove-derived Aspergillus fumigatus GXIMD 03099 fungus from Acanthus ilicifolius L. Their structures were elucidated by analysis of HRESIMS, NMR, and ESI-MS/MS data. Their absolute configurations were determined by X-ray diffraction analysis and Marfey's method. Compounds 1-8 were screened for insecticidal and antibacterial activities. Compound 2 showed insecticidal activity against newly hatched larvae of Culex quinquefasciatus with an LC50 value of 86.6 µM; compound 4 had weak activity against Vibrio harveyi with an MIC value of 5.85 µM.


Sujet(s)
Antibactériens , Aspergillus fumigatus , Insecticides , Tests de sensibilité microbienne , Peptides cycliques , Aspergillus fumigatus/effets des médicaments et des substances chimiques , Peptides cycliques/pharmacologie , Peptides cycliques/composition chimique , Peptides cycliques/isolement et purification , Animaux , Antibactériens/pharmacologie , Antibactériens/composition chimique , Antibactériens/isolement et purification , Insecticides/pharmacologie , Insecticides/composition chimique , Insecticides/isolement et purification , Vibrio/effets des médicaments et des substances chimiques , Culex/effets des médicaments et des substances chimiques , Larve/effets des médicaments et des substances chimiques , Structure moléculaire
7.
Sci Rep ; 14(1): 12825, 2024 06 04.
Article de Anglais | MEDLINE | ID: mdl-38834643

RÉSUMÉ

Cyclic tetrapeptides c(Pro-Phe-Pro-Phe) obtained by the mechanosynthetic method using a ball mill were isolated in a pure stereochemical form as a homochiral system (all L-amino acids, sample A) and as a heterochiral system with D configuration at one of the stereogenic centers of Phe (sample B). The structure and stereochemistry of both samples were determined by X-ray diffraction studies of single crystals. In DMSO and acetonitrile, sample A exists as an equimolar mixture of two conformers, while only one is monitored for sample B. The conformational space and energetic preferences for possible conformers were calculated using DFT methods. The distinctly different conformational flexibility of the two samples was experimentally proven by Variable Temperature (VT) and 2D EXSY NMR measurements. Both samples were docked to histone deacetylase HDAC8. Cytotoxic studies proved that none of the tested cyclic peptide is toxic.


Sujet(s)
Peptides cycliques , Peptides cycliques/composition chimique , Peptides cycliques/pharmacologie , Humains , Cristallographie aux rayons X , Histone deacetylases/métabolisme , Histone deacetylases/composition chimique , Simulation de docking moléculaire , Oligopeptides/composition chimique , Oligopeptides/pharmacologie , Stéréoisomérie , Solvants/composition chimique
8.
BMC Microbiol ; 24(1): 193, 2024 Jun 03.
Article de Anglais | MEDLINE | ID: mdl-38831400

RÉSUMÉ

INTRODUCTION: Optimal exploitation of the huge amounts of agro-industrial residuals that are produced annually, which endangers the ecosystem and ultimately contributes to climate change, is one of the solutions available to produce value-added compounds. AIM AND OBJECTIVES: This study aimed at the economic production and optimization of surfactin. Therefore, the production was carried out by the microbial conversion of Potato Peel Waste (PPW) and Frying Oil Waste (FOW) utilizing locally isolated Bacillus halotolerans. Also, investigating its potential application as an antimicrobial agent towards some pathogenic strains. RESULTS: Screening the bacterial isolates for surfactin production revealed that the strain with the highest yield (49 g/100 g substrate) and efficient oil displacement activity was genetically identified as B. halotolerans. The production process was then optimized utilizing Central Composite Design (CCD) resulting in the amelioration of yield by 11.4% (from 49 to 55.3 g/100 g substrate) and surface tension (ST) by 8.3% (from 36 to 33 mN/m) with a constant level of the critical micelle concentration (CMC) at 125 mg/L. Moreover, the physiochemical characterization studies of the produced surfactin by FTIR, 1H NMR, and LC-MS/MS proved the existence of a cyclic lipopeptide (surfactin). The investigations further showed a strong emulsification affinity for soybean and motor oil (E24 = 50%), as well as the ability to maintain the emulsion stable over a wide pH (4-10) and temperature (10-100 °C) range. Interestingly, surfactin had a broad-spectrum range of inhibition activity against Bacillus subtilis, Staphylococcus aureus, Pseudomonas aeruginosa, klebsiella pneumonia, and Candida albicans. CONCLUSION: Subsequently, the screening of the isolates and the utilized food-processing wastes along with the extraction technique resulted in a high yield of surfactin characterized by acceptable ST and CMC levels. However, optimization of the cultural conditions to improve the activity and productivity was achieved using Factor-At-A-Time (OFAT) and Central Composite Design (CCD). In contrast, surface activity recorded a maximum level of (33 mN/n) and productivity of 55.3 g/100 g substrate. The optimized surfactin had also the ability to maintain the stability of emulsions over a wide range of pH and temperature. Otherwise, the obtained results proved the promising efficiency of the surfactin against bacterial and fungal pathogens.


Sujet(s)
Bacillus , Déchets industriels , Lipopeptides , Solanum tuberosum , Bacillus/métabolisme , Bacillus/génétique , Bacillus/isolement et purification , Lipopeptides/pharmacologie , Lipopeptides/métabolisme , Lipopeptides/biosynthèse , Lipopeptides/composition chimique , Lipopeptides/isolement et purification , Solanum tuberosum/microbiologie , Peptides cycliques/pharmacologie , Peptides cycliques/composition chimique , Peptides cycliques/isolement et purification , Peptides cycliques/biosynthèse , Tests de sensibilité microbienne , Anti-infectieux/pharmacologie , Anti-infectieux/métabolisme , Anti-infectieux/composition chimique , Anti-infectieux/isolement et purification , Agriculture/méthodes
9.
Nat Commun ; 15(1): 4901, 2024 Jun 08.
Article de Anglais | MEDLINE | ID: mdl-38851779

RÉSUMÉ

Antimicrobial resistance remains a significant global threat, driving up mortality rates worldwide. Ribosomally synthesized and post-translationally modified peptides have emerged as a promising source of novel peptide antibiotics due to their diverse chemical structures. Here, we report the discovery of new aminovinyl-(methyl)cysteine (Avi(Me)Cys)-containing peptide antibiotics through a synergistic approach combining biosynthetic rule-based omics mining and heterologous expression. We first bioinformatically identify 1172 RiPP biosynthetic gene clusters (BGCs) responsible for Avi(Me)Cys-containing peptides formation from a vast pool of over 50,000 bacterial genomes. Subsequently, we successfully establish the connection between three identified BGCs and the biosynthesis of five peptide antibiotics via biosynthetic rule-guided metabolic analysis. Notably, we discover a class V lanthipeptide, massatide A, which displays excellent activity against gram-positive pathogens, including drug-resistant clinical isolates like linezolid-resistant S. aureus and methicillin-resistant S. aureus, with a minimum inhibitory concentration of 0.25 µg/mL. The remarkable performance of massatide A in an animal infection model, coupled with a relatively low risk of resistance and favorable safety profile, positions it as a promising candidate for antibiotic development. Our study highlights the potential of Avi(Me)Cys-containing peptides in expanding the arsenal of antibiotics against multi-drug-resistant bacteria, offering promising drug leads in the ongoing battle against infectious diseases.


Sujet(s)
Antibactériens , Staphylococcus aureus résistant à la méticilline , Tests de sensibilité microbienne , Animaux , Antibactériens/pharmacologie , Antibactériens/composition chimique , Staphylococcus aureus résistant à la méticilline/effets des médicaments et des substances chimiques , Staphylococcus aureus résistant à la méticilline/génétique , Peptides cycliques/pharmacologie , Peptides cycliques/composition chimique , Humains , Famille multigénique , Souris , Peptides antimicrobiens/pharmacologie , Peptides antimicrobiens/composition chimique , Peptides antimicrobiens/génétique , Peptides antimicrobiens/métabolisme , Infections à staphylocoques/traitement médicamenteux , Infections à staphylocoques/microbiologie , Résistance bactérienne aux médicaments/génétique , Résistance bactérienne aux médicaments/effets des médicaments et des substances chimiques , Génome bactérien/génétique , Staphylococcus aureus/effets des médicaments et des substances chimiques , Staphylococcus aureus/génétique , Biologie informatique/méthodes , Cystéine/métabolisme , Cystéine/composition chimique
10.
J Chem Inf Model ; 64(12): 4739-4758, 2024 Jun 24.
Article de Anglais | MEDLINE | ID: mdl-38863138

RÉSUMÉ

Despite recent success in the computational approaches of cyclic peptide design, current studies face challenges in modeling noncanonical amino acids and nonstandard cyclizations due to limited data. To address this challenge, we developed an integrated framework for the tailored design of stapled peptides (SPs) targeting the bromodomain of CREBBP (CREBBP-BrD). We introduce a powerful combination of anchored stapling and hierarchical molecular dynamics to design and optimize SPs by employing the MultiScale integrative conformational dynamics assessment (MSICDA) strategy, which involves an initial virtual screening of over 1.5 million SPs, followed by comprehensive simulations amounting to 154.54 µs across 5418 of instances. The MSICDA method provides a detailed and holistic stability view of peptide-protein interactions, systematically isolated optimized peptides and identified two leading candidates, DA#430 and DA#99409, characterized by their enhanced stability, optimized binding, and high affinity toward the CREBBP-BrD. In cell-free assays, DA#430 and DA#99409 exhibited 2- to 12-fold greater potency than inhibitor SGC-CBP30. Cell studies revealed higher peptide selectivity for cancerous versus normal cells over small molecules. DA#430 combined with (+)-JQ-1 showed promising synergistic effects. Our approach enables the identification of peptides with optimized binding, high affinity, and enhanced stability, leading to more precise and effective cyclic peptide design, thereby establishing MSICDA as a generalizable and transformative tool for uncovering novel targeted drug development in various therapeutic areas.


Sujet(s)
Protéine CBP , Simulation de dynamique moléculaire , Protéine CBP/composition chimique , Protéine CBP/métabolisme , Protéine CBP/antagonistes et inhibiteurs , Humains , Peptides cycliques/composition chimique , Peptides cycliques/pharmacologie , Peptides cycliques/métabolisme , Domaines protéiques , Conformation des protéines , Peptides/composition chimique , Peptides/métabolisme , Peptides/pharmacologie , Lignée cellulaire tumorale , Liaison aux protéines
11.
Anim Sci J ; 95(1): e13971, 2024.
Article de Anglais | MEDLINE | ID: mdl-38899765

RÉSUMÉ

This study investigated the effects of cyclic antimicrobial lipopeptides (CLPs) from Bacillus subtilis on the growth performance, gut morphology, and cecal gene expression and microbiota in broilers; 120 1-day-old unsexed Arbor Acres chicks were randomly divided into four groups, with six replicates in each group and five broilers per cage. These groups were fed a basal diet (C), basal diet plus 10-mg enramycin/kg (E), and basal diet plus 51-mg CLPs/kg (L) or 102-mg CLPs/kg (H). The results indicated that CLP supplementation linearly increased the body weight compared with the C group at 35 days of age. Between 15 and 35 days and 1 and 35 days of age, CLP supplementation linearly increased the average daily gain compared with the C group. The duodenal villus height was significantly increased in the H group compared with the C and E groups. In the cecum, CLP supplementation linearly increased SOD and ZO-1 mRNA expression compared with the C group. ß diversity of microbiota indicated distinct clusters between the groups. CLP supplementation linearly increased the abundance of the genus Lactobacillus in the cecal digesta compared with the C group. These results demonstrate that B. subtilis-produced CLPs dose-dependently increase broilers' growth performance, improve their gut morphology, and modulate their gut microbiota.


Sujet(s)
Bacillus subtilis , Caecum , Poulets , Régime alimentaire , Compléments alimentaires , Microbiome gastro-intestinal , Expression des gènes , Lipopeptides , Animaux , Poulets/croissance et développement , Poulets/microbiologie , Caecum/microbiologie , Microbiome gastro-intestinal/effets des médicaments et des substances chimiques , Lipopeptides/pharmacologie , Expression des gènes/effets des médicaments et des substances chimiques , Régime alimentaire/médecine vétérinaire , ARN messager/métabolisme , Aliment pour animaux , Peptides cycliques/pharmacologie , Peptides cycliques/administration et posologie , Lactobacillus , Intestins/anatomie et histologie , Intestins/microbiologie , Intestins/effets des médicaments et des substances chimiques
12.
Methods Enzymol ; 698: 263-299, 2024.
Article de Anglais | MEDLINE | ID: mdl-38886035

RÉSUMÉ

Quorum sensing (QS) is a density-dependent bacterial communication system that uses small molecules as regulatory modulators. Synthetic changes to these molecules can up-or-down-regulate this system, leading to control of phenotypes, like competence and virulence factor production, that have implications in human health. In this chapter, a methodology for library design and screening of synthetic autoinducing peptides (AIPs) to uncover QS SARs is delineated. Additionally, procedures for the synthesis, purification and analysis of linear and cyclic AIPs are detailed. This includes solutions for potential synthetic challenges including diketopiperazine formation when using N-methyl amino acids and cyclization of peptides containing N-terminal cysteine residues. These procedures have and are currently being applied to develop potent QS modulators in Streptococcus pneumoniae, Bacillus cereus, Streptococcus gordonii and Lactiplantibacillus plantarum.


Sujet(s)
Détection du quorum , Détection du quorum/effets des médicaments et des substances chimiques , Peptides cycliques/pharmacologie , Peptides cycliques/composition chimique , Humains , Peptides/pharmacologie , Peptides/composition chimique , Conception de médicament , Banque de peptides
13.
J Med Chem ; 67(11): 8693-8707, 2024 Jun 13.
Article de Anglais | MEDLINE | ID: mdl-38771638

RÉSUMÉ

Lactam cross-links have been employed to stabilize the helical secondary structure and enhance the activity and physiological stability of antimicrobial peptides; however, stabilization of ß-sheets via lactamization has not been observed. In the present study, lactams between the side chains of C- and N-terminal residues have been used to stabilize the ß-sheet conformation in a short ten-residue analogue of chicken angiogenin-4. Designed using a combination of molecular dynamics simulations and Markov state models, the lactam cross-linked peptides are shown to adopt stabilized ß-sheet conformations consistent with simulated structures. Replacement of the peptide side-chain Cys-Cys disulfide by a lactam cross-link enhanced the broad-spectrum antibacterial activity compared to the parent peptide and exhibited greater propensity to induce proinflammatory activity in macrophages. The combination of molecular simulations and conformational and biological analyses of the synthetic peptides provides a useful paradigm for the rational design of therapeutically active peptides with constrained ß-sheet structures.


Sujet(s)
Antibactériens , Simulation de dynamique moléculaire , Animaux , Antibactériens/pharmacologie , Antibactériens/composition chimique , Antibactériens/synthèse chimique , Peptides antimicrobiens/composition chimique , Peptides antimicrobiens/pharmacologie , Peptides antimicrobiens/synthèse chimique , Structure secondaire des protéines , Tests de sensibilité microbienne , Souris , Lactames/composition chimique , Lactames/pharmacologie , Lactames/synthèse chimique , Poulets , Peptides cycliques/composition chimique , Peptides cycliques/pharmacologie , Peptides cycliques/synthèse chimique , Peptides antimicrobiens cationiques/composition chimique , Peptides antimicrobiens cationiques/pharmacologie , Réactifs réticulants/composition chimique
14.
Int J Mol Sci ; 25(9)2024 Apr 24.
Article de Anglais | MEDLINE | ID: mdl-38731842

RÉSUMÉ

(1) Autophagy plays a significant role in development and cell proliferation. This process is mainly accomplished by the LC3 protein, which, after maturation, builds the nascent autophagosomes. The inhibition of LC3 maturation results in the interference of autophagy activation. (2) In this study, starting from the structure of a known LC3B binder (LIR2-RavZ peptide), we identified new LC3B ligands by applying an in silico drug design strategy. The most promising peptides were synthesized, biophysically assayed, and biologically evaluated to ascertain their potential antiproliferative activity on five humans cell lines. (3) A cyclic peptide (named Pep6), endowed with high conformational stability (due to the presence of a disulfide bridge), displayed a Kd value on LC3B in the nanomolar range. Assays accomplished on PC3, MCF-7, and A549 cancer cell lines proved that Pep6 exhibited cytotoxic effects comparable to those of the peptide LIR2-RavZ, a reference LC3B ligand. Furthermore, it was ineffective on both normal prostatic epithelium PNT2 and autophagy-defective prostate cancer DU145 cells. (4) Pep6 can be considered a new autophagy inhibitor that can be employed as a pharmacological tool or even as a template for the rational design of new small molecules endowed with autophagy inhibitory activity.


Sujet(s)
Autophagie , Conception de médicament , Peptides cycliques , Humains , Autophagie/effets des médicaments et des substances chimiques , Peptides cycliques/pharmacologie , Peptides cycliques/composition chimique , Peptides cycliques/synthèse chimique , Lignée cellulaire tumorale , Prolifération cellulaire/effets des médicaments et des substances chimiques , Antinéoplasiques/pharmacologie , Antinéoplasiques/composition chimique , Antinéoplasiques/synthèse chimique , Protéines associées aux microtubules/métabolisme , Simulation de docking moléculaire , Cellules A549 , Cellules MCF-7
15.
J Nat Prod ; 87(5): 1441-1453, 2024 May 24.
Article de Anglais | MEDLINE | ID: mdl-38722764

RÉSUMÉ

Herein, we report an extensive phytochemical study on the whole plant of Drymaria cordata, which led to the isolation of ten new orbitides, named drymariamides A-J (1-10). Compounds 2, 3, and 5 incorporate rare residues of noncanonical amino acids of kynurenine (Kyn) or 3a-hydroxypyrroloindoline (HPI). Their structures with absolute configurations were elucidated by a combination of spectroscopic analysis, advanced Marfey's method, X-ray diffraction, and electronic circular dichroism analysis. Compounds 1-10 exhibited antiadipogenic effects in 3T3-L1 adipocytes, and the most potent compound 7 showed an EC50 value of 1.17 ± 0.19 µM.


Sujet(s)
Cellules 3T3-L1 , Acides aminés , Peptides cycliques , Animaux , Souris , Acides aminés/composition chimique , Structure moléculaire , Peptides cycliques/composition chimique , Peptides cycliques/pharmacologie , Adipogenèse/effets des médicaments et des substances chimiques , Adipocytes/effets des médicaments et des substances chimiques , Adipocytes/métabolisme
16.
Bioorg Med Chem ; 106: 117733, 2024 May 15.
Article de Anglais | MEDLINE | ID: mdl-38704960

RÉSUMÉ

Development of selective or dual proteasome subunit inhibitors based on syringolin B as a scaffold is described. We focused our efforts on a structure-activity relationship study of inhibitors with various substituents at the 3-position of the macrolactam moiety of syringolin B analogue to evaluate whether this would be sufficient to confer subunit selectivity by using sets of analogues with hydrophobic, basic and acidic substituents, which were designed to target Met45, Glu53 and Arg45 embedded in the S1 subsite, respectively. The structure-activity relationship study using systematic analogues provided insight into the origin of the subunit-selective inhibitory activity. This strategy would be sufficient to confer subunit selectivity regarding ß5 and ß2 subunits.


Sujet(s)
Proteasome endopeptidase complex , Inhibiteurs du protéasome , Relation structure-activité , Proteasome endopeptidase complex/métabolisme , Proteasome endopeptidase complex/composition chimique , Inhibiteurs du protéasome/pharmacologie , Inhibiteurs du protéasome/composition chimique , Inhibiteurs du protéasome/synthèse chimique , Humains , Peptides cycliques/composition chimique , Peptides cycliques/pharmacologie , Sous-unités de protéines/antagonistes et inhibiteurs , Sous-unités de protéines/métabolisme , Sous-unités de protéines/composition chimique , Structure moléculaire
17.
Colloids Surf B Biointerfaces ; 239: 113933, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38729019

RÉSUMÉ

Lipopeptides produced by beneficial bacilli present promising alternatives to chemical pesticides for plant biocontrol purposes. Our research explores the distinct plant biocontrol activities of lipopeptides surfactin (SRF) and fengycin (FGC) by examining their interactions with lipid membranes. Our study shows that FGC exhibits a direct antagonistic activity against Botrytis cinerea and no marked immune-eliciting activity in Arabidopsis thaliana while SRF only demonstrates an ability to stimulate plant immunity. It also reveals that SRF and FGC exhibit diverse effects on membrane integrity and lipid packing. SRF primarily influences membrane physical state without significant membrane permeabilization, while FGC permeabilizes membranes without significantly affecting lipid packing. From our results, we can suggest that the direct antagonistic activity of lipopeptides is linked to their capacity to permeabilize lipid membrane while the stimulation of plant immunity is more likely the result of their ability to alter the mechanical properties of the membrane. Our work also explores how membrane lipid composition modulates the activities of SRF and FGC. Sterols negatively impact both lipopeptides' activities while sphingolipids mitigate the effects on membrane lipid packing but enhance membrane leakage. In conclusion, our findings emphasize the importance of considering both membrane lipid packing and leakage mechanisms in predicting the biological effects of lipopeptides. It also sheds light on the intricate interplay between the membrane composition and the effectiveness of the lipopeptides, providing insights for targeted biocontrol agent design.


Sujet(s)
Botrytis , Lipopeptides , Lipides membranaires , Peptides cycliques , Lipopeptides/pharmacologie , Lipopeptides/composition chimique , Peptides cycliques/pharmacologie , Peptides cycliques/composition chimique , Peptides cycliques/métabolisme , Lipides membranaires/métabolisme , Lipides membranaires/composition chimique , Botrytis/effets des médicaments et des substances chimiques , Arabidopsis/métabolisme , Membrane cellulaire/effets des médicaments et des substances chimiques , Membrane cellulaire/métabolisme , Antifongiques/pharmacologie , Antifongiques/composition chimique
18.
Org Lett ; 26(22): 4672-4677, 2024 Jun 07.
Article de Anglais | MEDLINE | ID: mdl-38787765

RÉSUMÉ

Picrachinentins A-F (1-6, respectively), six novel cyclopeptide alkaloid-type burpitides (CPABs), were isolated and fully elucidated from the EtOH extract of the stems and leaves of Picrasma chinensis. Structurally, compounds 1-6 have a 14-membered paracyclophane ring system that was closed through an ether bond between the ß-hydroxy amino acid and tyrosine and modified with a 4,5-methylenedioxybenzoyloxy (MDBz, 3 and 5) or hexanoyl (Hexa, 1, 2, 4, and 6) group at the N-terminus. Interestingly, this is the first report on the isolation and characterization of CPABs from plants of the Simaroubaceae family. In addition, all compounds showed a neuroprotective effect against H2O2-damaged SH-SY5Y cells. Compound 1 was further investigated for its neuroprotective activities using a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson's disease animal model, and it dramatically improved MPTP-impaired motor behavioral performance. Biochemical analysis revealed compound 1 restored the tyrosine hydroxylase expression in the striatum of the MPTP-damaged mouse brain, which demonstrates its protective effect on dopaminergic neurons.


Sujet(s)
Alcaloïdes , Neuroprotecteurs , Peptides cycliques , Picrasma , Neuroprotecteurs/pharmacologie , Neuroprotecteurs/composition chimique , Neuroprotecteurs/isolement et purification , Animaux , Peptides cycliques/composition chimique , Peptides cycliques/pharmacologie , Peptides cycliques/isolement et purification , Souris , Picrasma/composition chimique , Alcaloïdes/pharmacologie , Alcaloïdes/composition chimique , Alcaloïdes/isolement et purification , Structure moléculaire , Humains , Peroxyde d'hydrogène/pharmacologie , Peroxyde d'hydrogène/antagonistes et inhibiteurs , Feuilles de plante/composition chimique , 1-Méthyl-4-phényl-1,2,3,6-tétrahydropyridine/pharmacologie
19.
J Chem Inf Model ; 64(10): 4158-4167, 2024 May 27.
Article de Anglais | MEDLINE | ID: mdl-38751042

RÉSUMÉ

The cyclic peptide OS1 (amino acid sequence: CTERMALHNLC), which has a disulfide bond between both termini cysteine residues, inhibits complex formation between the platelet glycoprotein Ibα (GPIbα) and the von Willebrand factor (vWF) by forming a complex with GPIbα. To study the binding mechanism between GPIbα and OS1 and, therefore, the inhibition mechanism of the protein-protein GPIbα-vWF complex, we have applied our multicanonical molecular dynamics (McMD)-based dynamic docking protocol starting from the unbound state of the peptide. Our simulations have reproduced the experimental complex structure, although the top-ranking structure was an intermediary one, where the peptide was bound in the same location as in the experimental structure; however, the ß-switch of GPIbα attained a different conformation. Our analysis showed that subsequent refolding of the ß-switch results in a more stable binding configuration, although the transition to the native configuration appears to take some time, during which OS1 could dissociate. Our results show that conformational changes in the ß-switch are crucial for successful binding of OS1. Furthermore, we identified several allosteric binding sites of GPIbα that might also interfere with vWF binding, and optimization of the peptide to target these allosteric sites might lead to a more effective inhibitor, as these are not dependent on the ß-switch conformation.


Sujet(s)
Simulation de docking moléculaire , Simulation de dynamique moléculaire , Peptides cycliques , Complexe glycoprotéique GPIb-IX plaquettaire , Liaison aux protéines , Peptides cycliques/composition chimique , Peptides cycliques/pharmacologie , Peptides cycliques/métabolisme , Complexe glycoprotéique GPIb-IX plaquettaire/composition chimique , Complexe glycoprotéique GPIb-IX plaquettaire/métabolisme , Conformation des protéines , Facteur de von Willebrand/composition chimique , Facteur de von Willebrand/métabolisme , Humains , Sites de fixation
20.
Biotechnol Adv ; 73: 108371, 2024.
Article de Anglais | MEDLINE | ID: mdl-38704105

RÉSUMÉ

Natural products with antibacterial activity are highly desired globally to combat against multidrug-resistant (MDR) bacteria. Antibacterial peptide (ABP), especially cyclic ABP (CABP), is one of the abundant classes. Most of them were isolated from microbes, demonstrating excellent bactericidal effects. With the improved proteolytic stability, CABPs are normally considered to have better druggability than linear peptides. However, most clinically-used CABP-based antibiotics, such as colistin, also face the challenges of drug resistance soon after they reached the market, urgently requiring the development of next-generation succedaneums. We present here a detail review on the novel naturally-occurring CABPs discovered in the past decade and some of them are under clinical trials, exhibiting anticipated application potential. According to their chemical structures, they were broadly classified into five groups, including (i) lactam/lactone-based CABPs, (ii) cyclic lipopeptides, (iii) glycopeptides, (iv) cyclic sulfur-rich peptides and (v) multiple-modified CABPs. Their chemical structures, antibacterial spectrums and proposed mechanisms are discussed. Moreover, engineered analogs of these novel CABPs are also summarized to preliminarily analyze their structure-activity relationship. This review aims to provide a global perspective on research and development of novel CABPs to highlight the effectiveness of derivatives design in identifying promising antibacterial agents. Further research efforts in this area are believed to play important roles in fighting against the multidrug-resistance crisis.


Sujet(s)
Antibactériens , Peptides cycliques , Peptides cycliques/composition chimique , Peptides cycliques/pharmacologie , Antibactériens/pharmacologie , Antibactériens/composition chimique , Relation structure-activité , Humains , Peptides antimicrobiens/composition chimique , Peptides antimicrobiens/pharmacologie , Multirésistance bactérienne aux médicaments/effets des médicaments et des substances chimiques , Produits biologiques/composition chimique , Produits biologiques/pharmacologie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...